The PE Ratio as of November 2024 (TTM) for Arcus Biosciences, Inc. (RCUS) is -4.61

According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.61. This represents a change of -83.47% compared to the average of -27.88 of the last 4 quarters.

Arcus Biosciences, Inc. (RCUS) Historical PE Ratio (quarterly & annually)

How has RCUS PE Ratio performed in the past?

The mean historical PE Ratio of Arcus Biosciences, Inc. over the last ten years is -2.45. The current -4.61 PE Ratio has changed 18.69% with respect to the historical average. Over the past ten years (40 quarters), RCUS's PE Ratio was at its highest in in the September 2020 quarter at 147.22. The PE Ratio was at its lowest in in the March 2024 quarter at -99.56.

Arcus Biosciences, Inc. (RCUS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Arcus Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Arcus Biosciences, Inc. (RCUS) Average PE Ratio

How has RCUS PE Ratio performed in the past?

The current PE Ratio of Arcus Biosciences, Inc. (RCUS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Arcus Biosciences, Inc. (RCUS) PE Ratio vs. Peers

How is RCUS’s PE Ratio compared to its peers?

Arcus Biosciences, Inc.’s PE Ratio is greater than Cullinan Oncology, Inc. (-5.10), greater than Annexon, Inc. (-6.12), greater than Structure Therapeutics Inc. (-14.91), less than Relay Therapeutics, Inc. (-1.93), greater than Day One Biopharmaceuticals, Inc. (-15.73), less than Acumen Pharmaceuticals, Inc. (-1.74), less than X4 Pharmaceuticals, Inc. (-4.05), less than Inozyme Pharma, Inc. (-1.84), greater than VectivBio Holding AG (-7.94), greater than PTC Therapeutics, Inc. (-7.34), greater than Blueprint Medicines Corporation (-46.60), less than Krystal Biotech, Inc. (104.40), greater than Intercept Pharmaceuticals, Inc. (-91.78), greater than Madrigal Pharmaceuticals, Inc. (-14.57), less than Immix Biopharma, Inc. (-2.41), less than CNS Pharmaceuticals, Inc. (-0.16), less than Hepion Pharmaceuticals, Inc. (-0.20), less than Freeline Therapeutics Holdings plc (-1.01), less than AVROBIO, Inc. (2.07), greater than Icosavax, Inc. (-15.78), greater than Apellis Pharmaceuticals, Inc. (-15.24), less than iTeos Therapeutics, Inc. (-2.96), less than TScan Therapeutics, Inc. (-4.54),

Build a custom stock screener for Arcus Biosciences, Inc. (RCUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arcus Biosciences, Inc. (RCUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.